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The higher than initially expected prevalence of broadly neutralizing antibodies in HIV-infected individuals [5] [6] [7] has sparked optimism of the possibility of making a vaccine that can elicit them. However, the time it takes for HIV-infected people to develop these antibodies (which can be up to years 8 ) poses a big hurdle to HIV vaccine development. The article by Moore et al. 9 in this issue of Nature Medicine may shed some light into why the process of developing broadly neutralizing antibodies takes so long. The authors describe an HIV evolutionary pathway in which viral escape from a first antibody response that is directed against an epitope in the viral envelope C3 region is mediated through a shift of an envelope glycan from position 334 to position 332 ( Fig. 1) . This creates a new epitope that subsequently elicits the production of broadly neutralizing antibodies by the host immune response. Therefore, the escape viral variant with the relocated glycan, not the founder virus, is responsible for eliciting a broadly neutralizing antibody response.
The new data of Moore et al. 9 can be better understood in the context of the cocrystal structure of PGT128, a glycan-dependent broadly neutralizing antibody against HIV-1, in complex with the HIV-1 envelope gp120 outer domain 4 . This structure indicates that recognition of the HIV-1 envelope by PGT128 requires two closely spaced glycans at positions 301 and 332 at the base of the third variable domain (V3) in gp120, which form a glycan canyon that can be penetrated by the long CDR3 region of this antibody 4 (Fig. 1) . The HIV-1 escape mutation described by Moore et al. 9 shifts an N-linked glycan from position 334 to position 332. This reshapes the epitope from one that binds an HIV strain-specific antibody with a relatively large footprint on the variable protein surface of the spike into one with a glycan canyon with enough non-selfness for immune recognition and a smaller protein surface, thus creating a new conserved viral epitope (Fig. 1) . Interestingly, Moore et al. 9 discovered that there is a similar evolutionary path for the creation of the highly conserved glycan 160-based epitope of HIV-1. They found that the appearance of virus variants with the 332 glycan later in infection is common among HIV-1 clade C viruses, although not all patients can mount a broadly neutralizing immune response to that epitope. This implies that there are still unknown factors that influence whether broadly neutralizing antibodies will develop or not.
The identification of this HIV evolutionary pathway that drives the breadth of the host humoral immune response may provide new clues for the development of vaccine regimens. Although it is not known whether the first type-specific antibodies and the subsequent broadly neutralizing antibodies in the HIVinfected patients studied by Moore et al. 9 were from the same germ line, the pathway that they describe may indicate that affinity maturation of the first type-specific antibody is driven by the HIV-1 escape variant, affecting the broadly neutralizing antibody specificity. Their results could also imply that heterologous primeboost regimens using different HIV envelope epitopes may be required to elicit broadly neutralizing humoral immunity. The absence of the 332 glycan in a substantial proportion of HIV-1 clade C founder viruses may suggest that a vaccine containing only this epitope will have insufficient efficacy. Therefore, the inclusion of other HIV-1 epitopes, for instance, an epitope that includes the glycan at position 160, should be considered, because this epitope is relatively conserved among founder viruses. Finally, similar evolutionary studies on virus-host interactions in HIV-infected individuals who developed different broadly neutralizing antibody specificities will be required to obtain a more complete picture of potential heterologous prime-boost vaccine regimens that may be used to elicit protective broadly neutralizing antibodies.
The SIRTs are a family of class III histone deacetylases (HDACs), distinguished from other HDAC classes by their requirement for nicotinamide adenine dinucleotide (NAD) in the deacetylation reaction. SIRTs can catalyze deacetylation of histone and nonhistone lysines. The requirement for NAD constitutes an ancient and evolutionarily conserved mechanism that may link the expression of SIRT-regulated genes with metabolism and nutritional state 1 .
SIRTs were first discovered in yeast, in which an extra copy of SIR2 was shown to extend lifespan by 50%, whereas its deletion shortened lifespan 1 . In worms (Caenorhabditis elegans) and flies (Drosophila melanogaster) the respective SIR2 homologs seemed to similarly regulate lifespan, and in worms this regulation was found to be mediated by DAF-16, a homolog of human Forkhead (FOXO) transcription factors that regulate stress-related genes, apoptotic factors, antioxidants and metabolism 2, 3 . Regulation of glucose homeostasis is a recurring theme linking SIRTs with caloric restriction, aging and lifespan throughout evolution. Daf2, an insulin-like receptor that regulates PI3K, also regulates DAF-16 and is downregulated by Sir2 or caloric restriction 4 .
Compelling evidence now implicates each of the mammalian nuclear SIRTs 1, 6 and 7 in the regulation of aging, with links to metabolism, caloric restriction and, especially in the case of SIRT6, glucose homeostasis and the insulin npg volume 18 | number 11 | november 2012 nature medicine and insulin-like growth factor (IGF) signaling pathways 5, 6 . In this issue of Nature Medicine, Sundaresan et al. 7 now directly link SIRT6 with heart disease, which is currently the main determinant of human lifespan in Western populations. Their work shows that SIRT6 selectively downregulates multiple components of the IGF pathway in mouse hearts by binding the transcription factor c-Jun and directing its deacetylase activity selectively to gene promoters with binding sites for the transcription factor Fos/Jun (AP1). The authors show that SIRT6 expression is decreased in failing human hearts, and, in parallel transgenic mouse models, they present plausible evidence that SIRT6 deficiency-induced chronic activation of the IGF signaling pathway and its effectors promotes hypertrophic cardiomyopathy, adverse cardiac remodeling and heart failure ( Fig. 1) .
SIRT6-deficient mice show the most severe phenotype of all SIRT gene knockouts, with premature aging that includes features of osteoporosis, spinal curvature, absence of subcutaneous fat and severe metabolic imbalance, lymphopenia and acute onset hypoglycemia that results in death of mice within 1 month of age 2 . In contrast, transgenic overexpression of Sirt6 protects mice against the adverse consequences of a high-fat diet, including the 'metabolic syndrome' (characterized by obesity, insulin resistance, elevated serum triglycerides and cholesterol), which is commonly considered a forerunner of cardiovascular disease 6 .
SIRT6 selectively targets and deacetylates histone H3 lysine 9 (H3K9), and before the study by Sundaresan et al. 7 three SIRT6-specific targets had been identified that contribute to metabolic dysfunction and aging. The first targets to be discovered were H3K9 sites on human telomeres, at which deacetylation by SIRT6 was required to prevent telomeredependent genome instability and premature senescence 8 . Subsequently, it was shown that the RELA subunit of the transcription factor NF-κB selectively bound SIRT6, thus directing its deacetylase function to the chromatin of NF-κB-dependent genes and resulting in their silencing 9 . More recently, SIRT6 was shown to bind and exert similar control over HIF1-α−regulated genes, and increased expression of genes encoding products such as glucose transporters and glycolytic enzymes in Sirt6-knockout mice substantially accounted for their hypoglycemia phenotype and premature death 10 .
The studies by Sundaresan et al. 7 identify a new cardiomyopathy phenotype of SIRT6-deficient mice and shed additional light on the targets and mechanism of action of SIRT6 that may be relevant to heart disease and, consequently to life span, if the results extend to humans. Using Sirt6-knockout mice that survive up to 1 year of age (due to backcrossing the original 129sv strain with Black Swiss/FVB mice), the authors showed that these mice age more rapidly compared with wild-type mice on the same background and develop classical symptoms of hypertrophic cardiomyopathy (HCM), with contractile dysfunction, chamber dilation and, ultimately, heart failure. To confirm that SIRT6 has a heart-selective role, the authors showed that cardiac-specific deletion of Sirt6 conferred the same cardiomyopathy as whole-body knockout of Sirt6. The Sirt6-knockout phenotype includes defects in mitochondrial structure and organization, increased apoptosis and overexpression of fetal cardiac genes, typical of classical HCM. Sundaresan et al. 7 then showed that SIRT6-overexpressing transgenic mice were protected from HCM that was either driven pharmacologically or caused by pressure overload.
The authors attribute the cardiomyopathy in Sirt6-knockout mice to overactivity of the IGF-Akt pathway caused by SIRT6 deficiency. Whereas acute activation of this pathway is known to be protective in the setting of acute myocardial infarction, there is also evidence that chronic IGF-Akt overactivity mediates hypertrophic growth 11 . Sundaresan et al. 7 found that the hearts of Sirt6-knockout mice had elevated levels of the pathway members IGF-1R, InsR, Akt, GSK3 and IGF-2 and increased activities of multiple signaling components and downstream effectors, including Figure 1 Derepression of IGF signaling-related genes and hypertrophic cardiomyopathy by SIRT6 deficiency. Sundaresan et al. 7 provide evidence to suggest that in healthy individuals SIRT6 suppresses IGF signaling-related genes by binding and silencing expression from AP1-dependent promoters, and this contributes to metabolic homeostasis and the maintenance of a healthy heart. Low expression of SIRT6 possibly caused by a high-fat diet, sedentary lifestyle and/or genetics results in reduced SIRT6 silencing, and overexpression of IGF and possibly also of other AP1-dependent genes, thus promoting cardiomyopathy, heart failure and early death. Ac, acetylated H3K9. 7 extra polate to the human heart, SIRT6 may be a new susceptibility marker for HCM and, possibly, a therapeutic target. The regulation of SIRT6 and dysregulation during HCM becomes an important issue. Clearly, energy state and diet could have roles because SIRT6 expression is responsive to caloric restriction. Interestingly, SIRT1 is also regulated by caloric restriction and can bind and activate the SIRT6 promoter, possibly amplifying the response to caloric restriction, diet or both 12 . AP1 is now the third SIRT6-regulated transcription factor to be identified, and, along with NF-κB and HIF-1α, it also regulates major stress response pathways. It may also be pertinent that the opposing histone acetyltransferase activity eIF4E, S6P and p70S6K. They found no hypoglycemia and no changes in the expression of NF-κB-or HIF-1α-dependent genes in these mice. Nicotinamide, a sirtuin inhibitor, and PQ401, a partially selective inhibitor of IGF signaling, both rescued the cardiomyopathy in Sirt6-knockout mice, supporting direct roles for SIRT6 and the IGF pathway in heart disease.
To define the underlying mechanism, the authors used chromatin immunoprecipitation assays to show that SIRT6 binds the promoters of IGF-related genes, and they found that H3K9 at these sites was hypoacetylated in Sirt6-knockout mice. Using in silica analyses, they revealed that AP1-binding sites are common to multiple IGF-responsive gene promoters, implicating these as candidate targets for SIRT6. Indeed, the results confirm that the AP1 component c-Jun is a binding partner for SIRT6, allowing its deacetylase activity to be selectively delivered to AP1 sites of IGF-related genes in the heart and theoretically allowing the Small airways, big challenge: measuring the unseen?
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An imaging technique adapted to differentiate between chronic obstructive pulmonary disease phenotypes can identify small-airway pathophysiology, locate the disease and potentially track disease progression. This approach may be used as a biomarker to identify the small-airway lesion in chronic obstructive pulmonary disease, at an individual level in the clinic (pages 1711-1715).
